A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

A Phase 2B, Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.

Inclusion Criteria:

• Is obese with a body mass index (BMI) >=30 kg/m^2 to <=50 kg/m^2, and has been obese for at least one year before screening.
• Usually consumes at least three major meals (morning, midday, and evening) each day.

Exclusion Criteria:

• Is currently enrolled in a formal weight-loss program.
• Has had liposuction within 1 year before screening or is planning to have liposuction during the study.
• Has received any investigational drug within 3 months before screening.
• Has previously participated in a study using pramlintide.